PUBLISHER: Visiongain Reports Ltd. | PRODUCT CODE: 1127654
PUBLISHER: Visiongain Reports Ltd. | PRODUCT CODE: 1127654
Contact us about how to customize the report with add-on data.
The global mRNA Vaccines & Therapeutics market was valued at US$58,452.6 million in 2021 and is projected to change at a CAGR of -7.89% during the forecast period 2022-2032.
“The mRNA Vaccines & Therapeutics Market Report 2022-2032”: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
A successful application of mRNA technology for COVID-19 has reinvigorated biopharmaceutical companies to further explore opportunities of this technology for other diseases. There has been a significant increase in therapeutic mRNA programs that are focused on mRNA and its delivery platform, which is the major challenge for the delivery of mRNA into the cells. The Contract Development and Manufacturing Organisations (CDMOs) have also been compelled to ramp in their production capabilities to meet this surge in demand. Many existing CDMOs have made huge capital investments through developing and upgrading their manufacturing capabilities and processes to match GMP standards for vaccine development. These companies are making strategic partnerships and acquisitions to fortify their mRNA manufacturing technologies. For instance, Korea-based Samsung Biologics had signed an agreement with Moderna in May 2021 for aseptic fill-finish and packaging and labeling of Moderna's COVID-19 mRNA vaccine. In August 2021 Samsung Biologics announced its plan in three areas which included capacity expansion setting up an R&D center in the U.S. for support of its clients at a global scale, and expansion of the platform to support diverse applications.
You need to discover how this will impact the mRNA Vaccines & Therapeutics market today, and over the next 10 years:
This report tells you TODAY how the mRNA Vaccines & Therapeutics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, ""V" ", "L", "W" and "U" are discussed in this report.
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:
The report also includes profiles and for some of the leading companies in the mRNA Vaccines & Therapeutics Market Report 2022-2032, with a focus on this segment of these companies' operations.
Overall world revenue for mRNA Vaccines & Therapeutics Market, 2022 to 2032 in terms of value the market will surpass US$64,338 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
In summary, our 410+ page report provides you with the following knowledge:
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the mRNA Vaccines & Therapeutics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.
7.6.3.1.1.1 Viral Vector Market by Region, 2022-2032 (US$ Mn)
7.6.3.1.1.2 Viral Vector Market Share by Region, 2022-2032 (%)
7.6.3.2.1 Non-Viral Market by Region, 2022-2032 (US$ Mn)
7.6.3.2.2 Non-Viral Market Share by Region, 2022-2032 (%)
7.6.3.3.1.1 Lipid Nanoparticles (LNP)
7.6.3.3.1.2 Peptide-based Vectors
7.6.3.3.1.3 Polymer-based Vectors